AOD-9604 half life: what the human data actually shows

Last updated 2026-07-25

What is AOD-9604's actual half life in humans?

Here's the honest answer: there isn't a solid, publicly available human pharmacokinetic study that pins down AOD-9604's half life with a clean number in minutes or hours. That's unusual for a peptide this widely discussed, and it's worth sitting with for a second before moving on. The compound is a 15-amino-acid fragment of human growth hormone, covering roughly the 176-191 region, built to isolate the fat-metabolizing (lipolytic) piece of the hGH molecule while dropping out the growth-promoting piece. That design logic is well documented in the peptide literature ^{[1] [2]}. But design logic isn't pharmacokinetics. Knowing what a molecule is built to do tells you nothing about how fast your body clears it. Most of what circulates online about a 30-minute or 1-2 hour half life for AOD-9604 traces back to manufacturer data sheets, forum posts, and inference from full-length hGH fragment behavior, not to a peer-reviewed human trial with drawn blood samples and a clearance curve. If you've seen a specific number quoted with confidence, ask where it comes from. In most cases nobody can point to a citable source, and that gap is the real story here. The closest thing to hard human data on AOD-9604 comes from the clinical trial program run by Metabolic Pharmaceuticals in the early 2000s, referenced in a 2004 review in Current Opinion in Investigational Drugs ^[3] and in a follow-up review of obesity drugs in development ^[4]. Those papers describe efficacy findings, not a formal PK breakdown with half life values reported in the abstract or commonly cited text.

Why doesn't a clear half life number exist for AOD-9604?

Small peptides like AOD-9604 tend to get cleared fast. Renal filtration and peptidase breakdown are the two main routes for peptides in this size class, and a 15-residue fragment with no long fatty acid chain attached (unlike some other GH-related peptides) would be expected to clear quickly by that logic. But expected and measured are different things. The clinical trial program behind AOD-9604 was run by Metabolic Pharmaceuticals, an Australian company, through Phase IIb testing before development wound down. The 2004 review documents metabolic findings from that program ^[3], and it's the primary citable human data source most researchers point to. A separate 2006 review of obesity drugs then in the development pipeline places AOD-9604 in that broader competitive landscape ^[4], again without publishing a standalone PK half life figure that's since become a standard reference. That's the pattern with a lot of peptides that never reached full regulatory approval: the PK studies that would normally answer this question either weren't run at the scale needed, weren't published in a form indexed and cited widely, or were done in-house by the sponsor and never made it into a flagship journal. Absence of a widely cited number doesn't mean nobody ever measured anything. It means the public record, as it stands via PubMed-indexed literature, doesn't give researchers a number to point to with confidence.

Does AOD-9604's half life matter if the trials didn't show weight loss?

This is the part that actually matters more than the half life question, so let's be straight about it: AOD-9604 went through human obesity trials, and the weight-loss results did not separate convincingly from placebo. The 2004 review in Current Opinion in Investigational Drugs describes the metabolic profile from that trial program ^[3]. The compound was designed on a real piece of biology, the fat-mobilizing fragment of the hGH molecule, and that rationale isn't nonsense. hGH does have lipolytic activity, and isolating just that fragment to avoid the growth-related and insulin-resistance side effects of full hGH was a reasonable idea on paper. The 2006 review of the obesity drug pipeline includes AOD-9604 among the compounds being tracked at the time ^[4]. But a reasonable rationale and a positive trial result are two different things. Phase IIb obesity trials for AOD-9604 did not deliver the separation from placebo that would justify calling this compound an established fat-loss therapy. That's the central fact anyone researching this peptide needs before they get lost in dosing schedules or half life speculation. If the underlying efficacy signal is weak, then optimizing injection timing around a guessed half life is arranging deck chairs. If you're deciding whether to spend money and time on this compound, that's the fact to weigh first. For a broader look at what the trial data does and doesn't support, see aod 9604 peptide.

How does AOD-9604's half life compare to other peptides used for fat loss?

Since there's no solid published number for AOD-9604 itself, direct comparison is hard to do honestly. What's fair to compare is the class of compound and the depth of the evidence base behind it. Tesamorelin is a useful contrast. It's an FDA-approved growth hormone releasing hormone (GHRH) analog with a documented approval pathway you can verify in the Drugs@FDA database ^[5], meaning it has gone through the kind of controlled trial and PK characterization that AOD-9604 has not. That's a meaningfully different evidence tier, more than a different molecule.

For a fuller side-by-side on mechanism and evidence quality, see aod 9604 vs tesamorelin. The short version: tesamorelin has an approval file behind it. AOD-9604 has a discontinued trial program and a metabolic review paper. That's not a subtle difference.

Does AOD-9604's half life affect how it's dosed?

In theory, yes. In practice, most dosing schedules you'll see for AOD-9604 (once daily, sometimes twice, usually fasted or before meals) are built on assumption and convention borrowed from other peptides, not from a published human PK curve specific to this compound. A short-acting peptide would, in principle, need more frequent dosing to keep any effect going, and a fasted-state injection schedule is a common convention across the fragment/GH-peptide category based on the idea that insulin spikes might blunt lipolytic signaling. That's a mechanistic guess, not something demonstrated in a dedicated AOD-9604 trial with timed blood draws. If you're looking at reconstitution and timing questions specifically, how to reconstitute AOD-9604 and when to take AOD-9604 peptide cover the practical mechanics people actually ask about. But be clear-eyed that the timing advice out there is built on inference layered on inference, not on a half life number anyone can cite to a journal page.

Is AOD-9604 detected in a doping test, and does that relate to half life?

Detection window questions get lumped in with half life questions, but they're not the same thing, and here the data is actually solid. A 2013 study in Drug Testing and Analysis found that AOD-9604 does not interfere with the WADA human growth hormone isoform immunoassay, meaning it doesn't cause a false positive or false negative on that specific screening test ^[6]. That's a real, citable finding. It doesn't tell you how long AOD-9604 stays detectable in urine or blood, but it does tell you the standard hGH isoform test isn't confused by its presence. Separately, anti-doping labs have developed dedicated small-peptide detection methods. A 2016 paper in the Journal of Separation Science describes a direct urine injection method using liquid chromatography and ion mobility mass spectrometry built to screen peptides under 2 kDa, a category that includes AOD-9604 given its roughly 1.8 kDa mass ^[7]. A broader 2014 review in Expert Review of Proteomics covers detection strategies for peptidic drugs and analogs in sports doping generally, AOD-9604 included as a compound of interest ^[8], and a related 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis discusses analytical approaches for catching emerging, non-approved compounds in doping controls ^[9]. None of these papers report a half life figure. They confirm the compound is on anti-doping radar and can be picked up by dedicated small-molecule peptide screening, which is a separate and better-documented fact than its clearance rate in a recreational user's bloodstream.

What do recent reviews say about AOD-9604's evidence base overall?

Two more recent papers put AOD-9604 in context alongside other peptides used off-label in sports and orthopaedic settings, and neither treats it as a settled, well-characterized drug. A 2026 paper in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopaedics, including applications, challenges, and future directions for the category ^[1]. A separate 2026 paper in Sports Medicine reviews safety and efficacy data for approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance ^[2]. Both papers treat AOD-9604 as part of a wider unapproved-peptide landscape rather than as a compound with a mature, settled clinical and pharmacokinetic profile. That framing matters. When a peptide shows up in review papers about "challenges" and "unapproved" therapies rather than in FDA prescribing information with a stated half life in hours, that's the evidence tier you're actually working with. It's not damning on its own, plenty of legitimate compounds start there, but it should calibrate how much confidence you put in any specific number someone quotes you for half life, dosing frequency, or expected fat-loss effect.

Does AOD-9604 have any legal path to being compounded or prescribed?

This is a regulatory question, not a pharmacokinetic one, but it comes up in the same searches, so it's worth being precise about. Compounding pharmacies in the US operate under section 503A of the Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a ^[10], which allows compounding using bulk drug substances that meet specific criteria, including substances on FDA's 503A bulks list under 21 CFR 216.23 ^[11]. Outsourcing facilities registered under 503B operate under a parallel bulks list at 21 CFR 216.24 ^[12]. FDA maintains and updates the substances nominated for these lists on a public tracking page ^[13], and you can check current status of any substance there rather than taking a seller's word for it. Separately, 21 CFR 201.128 defines "intended use" for drug labeling purposes , which is the regulatory hook FDA uses when a product is marketed with disease-treatment claims it isn't approved to make. AOD-9604 has never gone through the Drugs@FDA approval process ^[5], and its bulk-substance status for compounding purposes is something a buyer should verify directly against FDA's current lists rather than assume.

Where AOD-9604 fits if you're weighing options

If you're this deep into half life and PK questions, you're probably trying to decide whether AOD-9604 is worth pursuing at all compared to other options. Here's the straight take. The mechanistic story (isolating hGH's lipolytic fragment to dodge growth and insulin side effects) is a legitimate scientific idea, and it's the reason Metabolic Pharmaceuticals took it through Phase IIb trials in the first place ^{[3] [4]}. But the human obesity trial data that came out of that program didn't show weight loss separating convincingly from placebo. That's the fact that should weigh most heavily in any decision, more than a half life number nobody can definitively source. If you're going to look further into this compound anyway, do it with eyes open about the evidence tier you're in: discontinued trials, no FDA approval, no widely cited human PK paper, and detection methods built primarily for anti-doping labs rather than clinical dosing guidance. For sourcing questions specifically, AOD-9604 peptide for sale and best place to buy AOD-9604 cover what a provider-reviewed, pharmacy-fulfilled route actually looks like versus buying from an unverified research-chemical seller. That distinction matters more for your safety than any half life estimate does.

Frequently asked questions

What is the half life of AOD-9604 in the human body?

There's no widely cited, peer-reviewed human pharmacokinetic study that establishes a specific half life figure for AOD-9604. Numbers circulating online (often 30 minutes to a couple hours) trace back to manufacturer sheets and inference from similar peptides, not a published clearance study with citable data.

How long does AOD-9604 stay in your system?

Nobody has published a definitive human clearance timeline for AOD-9604. As a roughly 1.8 kDa peptide fragment, it would be expected to clear relatively fast via renal filtration and peptidase breakdown, similar to other small peptides, but that's an inference from molecular class, not a measured result specific to this compound.

Why don't we have a clear AOD-9604 half life study?

AOD-9604's clinical development, run by Metabolic Pharmaceuticals, reached Phase IIb before stopping. A 2004 review documents metabolic trial findings ^[1], but a standalone PK half life figure was never published in a form that's become a standard, widely cited reference in the literature.

Does AOD-9604 actually cause fat loss in humans?

The human obesity trial program behind AOD-9604 did not show weight loss results that separated convincingly from placebo, per the 2004 review of the trial's metabolic findings ^[1] and the 2006 review placing it in the broader obesity drug pipeline ^[4]. The rationale is real biology; the trial outcome was weak.

Is AOD-9604 approved by the FDA?

No. AOD-9604 does not appear in Drugs@FDA, the FDA's database of approved drug products ^[5]. It never completed the trial and approval process required for that listing, and its Phase IIb obesity program did not lead to a marketing approval.

Does AOD-9604 show up on a drug test?

A 2013 study in Drug Testing and Analysis found AOD-9604 does not interfere with the WADA hGH isoform immunoassay ^[6]. Separate small-peptide detection methods, including a 2016 urine injection LC/ion mobility mass spec method for peptides under 2 kDa, have been developed specifically to catch compounds like it ^[7].

How is AOD-9604's half life different from tesamorelin's?

Tesamorelin is FDA approved and its pharmacokinetic profile has been characterized as part of that approval process, verifiable in Drugs@FDA ^[5]. AOD-9604 has no comparable published PK characterization and never reached FDA approval, so a direct half life comparison isn't possible from public data.

Should half life determine how often I inject AOD-9604?

In theory a shorter half life would call for more frequent dosing, but no dedicated human PK study backs the common once or twice daily schedules seen online for AOD-9604. Those schedules are largely convention borrowed from other GH-related peptides, not derived from measured clearance data specific to this compound.

Can AOD-9604 be legally compounded by a US pharmacy?

Compounding is governed by 21 U.S.C. 353a and FDA's 503A and 503B bulk drug substance lists (21 CFR 216.23 and 216.24) ^[12][13][14]. Whether AOD-9604 qualifies depends on its current status on those FDA-maintained lists, which buyers should check directly rather than rely on a seller's claim.

What does the fragment rationale behind AOD-9604 actually mean?

AOD-9604 covers roughly amino acids 176-191 of human growth hormone, the region researchers link to hGH's fat-mobilizing (lipolytic) activity, without the growth-promoting or insulin-resistance-related effects of the full hormone. It's a reasonable scientific idea, discussed in reviews of the obesity drug pipeline ^[4], but the idea didn't translate into a clear trial win ^[1].

Are there newer studies on AOD-9604's safety or use in other conditions?

Yes. A 2026 orthopaedics review covers therapeutic peptides including AOD-9604 in that broader category ^[10], and a 2026 Sports Medicine review covers safety and efficacy of approved and unapproved peptide therapies for musculoskeletal and performance use ^[11]. Neither establishes a settled PK profile; both treat it as part of an evolving, unapproved-peptide landscape.

Where should I go for the practical dosing and sourcing details?

For reconstitution mechanics see how to reconstitute AOD-9604, for timing conventions see when to take AOD-9604 peptide, and for sourcing through a provider-reviewed, pharmacy-fulfilled route see best place to buy AOD-9604.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): 2004 review documents metabolic findings from AOD-9604's human trial program; weight-loss results did not separate convincingly from placebo
2. PubMed, JAAOS Global Research & Reviews (2026): Review of therapeutic peptides in orthopaedics, including applications and challenges for compounds like AOD-9604
3. PubMed, Sports Medicine (2026): Review of safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance
4. PubMed, Current Opinion in Investigational Drugs (2006): 2006 review places AOD-9604 in the broader obesity drug development pipeline of that era
5. FDA, Drugs@FDA database: AOD-9604 does not appear as an FDA-approved drug product; tesamorelin's approval status can be verified in this database
6. PubMed, Drug Testing and Analysis (2013): AOD-9604 does not influence or interfere with the WADA human growth hormone isoform immunoassay
7. PubMed, Journal of Separation Science (2016): Direct urine injection LC and ion mobility mass spectrometry method developed to screen peptides under 2 kDa, a category including AOD-9604
8. PubMed, Expert Review of Proteomics (2014): Review of detection strategies for peptidic drugs and analogs, including AOD-9604, in sports doping controls
9. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Analytical approaches developed for detecting emerging, non-approved therapeutic compounds in human doping controls
10. Cornell Law School, 21 U.S.C. 353a: Section 503A of the FDCA governs pharmacy compounding and bulk drug substance use requirements
11. eCFR, 21 CFR 216.23: Final 503A bulk drug substances list that compounding pharmacies must reference for allowed substances
12. eCFR, 21 CFR 216.24: 503B bulk drug substances list applicable to registered outsourcing facilities
13. FDA, bulk drug substances nominated for use in compounding: FDA's current tracking list of substances nominated for 503A/503B compounding use, which buyers can check for a given compound's status